67 results about "Antibody level" patented technology

The invention relates to the field of immunology, and discloses a polypeptide and a kit for distinguishing bovine and sheep brucella natural infection from a vaccine immune antibody. Polypeptides as shown in SEQ ID NO: 1 and SEQ ID NO: 2 are artificially synthesized and used as antigens to coat an elisa plate and a nitrocellulose membrane, and according to response characteristics of antibody level, identification and detection of natural infection and vaccine immunity of cattle and sheep populations are realized. The peptide fragment and the detection kit provided by the invention can make up the blank of identifying bovine and sheep brucella natural infection and immune antibodies. The method solves the problem that the antibody induced by the attenuated live vaccine and the naturally infected antibody are difficult to distinguish, provides a scientific basis for quarantine and purification of Brucella, and provides a technical guarantee for preventing human diseases and animals, advancing the mouth and protecting the body health of people.

AAV vectors are ideally suited for long-term delivery of a combination of broadly neutralizing antibodies to achieve sterilizing immunity to HIV. Unfortunately, host immune responses to the delivered antibody have severely limited the efficacy. The TLR9 pathway has been identified in initiating adaptive immune responses against AAV and delivered bNAbs. To enhance this strategy, we validated Hydroxychloroquine, a known drug inhibitor of the TLR9 pathway, as a pretreatment to AAV delivery to avoid anti-drug antibody responses. TLR9 signaling inhibition was validated using a HEK-Blue hTLR9 reporter cell line and CpG stimulation. Hydroxychloroquine was also validated in a 3-macaque trial where AAV9-3BNC117 and AAV9-10-1074 were administered along with 3 doses of hydroxychloroquine once a week starting 1 week before AAV inoculation. Unlike historical controls, where 3BNC117 and 10-1074 expression is lost within the first 4-5 weeks, 2 macaques maintained 10-1074 expression and 1 macaque maintained 3BNC117 for the duration of the trial. Anti-3BNC117 antibodies were only observed in 2 of the 3 macaques and were significantly delayed. Anti-10-1074 antibody responses were a log lower than typically observed in historic controls. The use of hydroxychloroquine as a pretreatment for AAV inoculation is a promising strategy. The significant decrease in anti-10-1074 antibody levels and the successful delivery of 10-1074 in 2 macaques and 3BNC117 in 1 macaque was very encouraging. Extending the dosage of hydroxychloroquine beyond 3 doses may be sufficient to observe long-term bNAb expression in all animals and further decrease ADA responses. Together, these data suggest that the short-term treatment of hydroxychloroquine at the time of AAV inoculation has a meaningful impact on tolerance induction to our AAV-delivered bNAbs.

This invention relates to the field of traditional Chinese medicine and natural medicines, and discloses a traditional Chinese medicine composition for treating thyroiditis, nodular goiter, and thyroid nodules, as well as its preparation method and application. The traditional Chinese medicine composition is made from raw materials in parts by weight of 1-30 parts of Prunella vulgaris, 1-30 parts of Taraxacum mongolicum, 1-30 parts of Hordeum vulgare malt, 1-20 parts of Citrus reticulata peel, 1-24 parts of Crataegus pinnatifida, and 1-24 parts of Raphanus sativus seed. It can not only significantly reduce serum TgAb and TPOAb antibody levels, inhibiting the attack of autoimmune response on the thyroid gland from the source, but also effectively reduce lymphocyte infiltration, repair damaged thyroid follicular structure and restore colloid content, thereby reversing immune damage and tissue destruction of the thyroid gland, reducing thyroid nodules, and solving the problems of existing treatments for thyroiditis, nodular goiter, and thyroid nodules that cannot reverse immune damage to the thyroid gland, destruction of follicular structure, and tissue fibrosis.

The application discloses a preparation method of a tetravalent influenza virus split vaccine and belongs to the technical field of vaccines. The preparation method of the tetravalent influenza virus split vaccine comprises the following steps: pre-incubation of a chicken embryo, pre-embryo inspection, virus inoculation and culture, post-embryo inspection, cold embryo, virus harvesting, ultrafiltration clarification, zone centrifugation, desugaring, chromatography, virus splitting, virus inactivation, ultrafiltration liquid replacement, sterilization filtration and preparation of a tetravalent influenza virus split vaccine product. Compared with the prior art, the technical means adopted in the application effectively reduces the content of free formaldehyde and improves the antibody level of the vaccine.

The application belongs to the technical field of biotechnology, and discloses a nano antibody targeting B cell BCMA and application thereof. The amino acid sequences of the complementarity determining regions CDR1-CDR3 of the nano antibody are selected from SEQ ID NO. 1-12. The nano antibody provided by the application can specifically bind to B cells in human blood, especially activated plasma cells, so as to eliminate B cells producing pathological antibodies. Compared with traditional antibodies, the nano antibody provided by the application has a smaller molecular weight, high stability, low cost, easy expression and high expression amount, and is suitable for large-scale production. The nano antibody is combined with a solid-phase carrier in the application, so that B cells in blood can be targeted and eliminated, the number of B cells in blood of patients can be reduced in a short time, and the antibody level can be reduced, thereby improving the quality of life, reducing complications, and providing a new treatment option for patients who are ineffective or intolerant to traditional treatment.

The application discloses a chicken Newcastle disease, avian influenza and chicken infectious rhinitis triple inactivated vaccine and preparation and application thereof, and relates to the technical field of bioengineering. The application discloses a preparation method and application of a chicken Newcastle disease, avian influenza and chicken infectious rhinitis (A, B and C three serotypes) subunit protein triple inactivated vaccine. The preparation method comprises the following steps: constructing and expressing a serum B paracolon avian bacillus subunit protein expression strain; and preparing the chicken Newcastle disease, H9 subtype avian influenza and chicken infectious rhinitis (A, B and C three serotypes) subunit protein triple inactivated vaccine at a certain ratio. The triple inactivated vaccine has good safety, can be used for the prevention of chicken Newcastle disease, H9 subtype avian influenza and A, B and C three serotypes paracolon avian bacillus diseases in a laying hen group, and does not cause the decrease of the laying rate after immunization. Meanwhile, the paracolon avian bacillus subunit protein can improve the antibody level of the Newcastle disease and the H9 avian influenza, and the protection of the vaccine on the A, B and C three serotypes paracolon avian bacillus can reach 100%.

The present application provides methods, compositions and kits for determining SHD-catalyzed antibody levels in a biological sample and for treating or preventing protein aggregation disease (PAD) in an individual. Catalytic antibodies that specifically recognize amyloid beta (A beta) peptides and methods of using the same are also provided.

The invention belongs to the technical field of biological medicines, and particularly relates to a compound protein preparation for preventing and treating avian influenza and a preparation method thereof. The compound protein preparation is prepared from the following raw materials in parts by weight: 5 to 10 parts of immune globulin, 15 to 19 parts of radix puerariae, 10 to 15 parts of buchnera macrocarpa, 8 to 12 parts of dendranthema morifolium, 7 to 10 parts of honeysuckle flower, 3 to 10 parts of radix astragali seu hedysari, 2 to 8 parts of echinacea purpurea, 1 to 7 parts of semen cuscutae and 2 to 5 parts of liquorice root. By taking the compound protein preparation for preventing and treating the avian influenza, clinical symptoms caused by the avian influenza can be effectively relieved, and the health level of animals is improved; the vaccine-induced immune response can be effectively enhanced, so that the avian influenza antibody level of animals is improved, the avian influenza is effectively prevented and treated, and the vaccine has a wide application prospect.

This invention belongs to the field of molecular marker technology, specifically relating to SNP molecular markers, primers, and applications of the PRRX2 gene associated with African swine fever virus (ASFV) antibody levels. The SNP molecular marker is located at 143 bp of exon 3 of the porcine PRRX2 gene (genotype XM_005654574.2), exhibiting T / C polymorphism. The nucleotide sequence of the SNP molecular marker is shown in SEQ ID NO.3. The molecular marker provided by this invention is closely associated with ASFV antibody levels in pigs. Compared to pigs with the TC / CC genotype at this locus, pigs with the TT genotype have higher ASFV antibody levels in their serum. This molecular marker can be applied to breed high-quality breeding pigs resistant to ASFV, thereby effectively improving the economic benefits of pig farming.

Provided herein are methods for administering hepatitis B virus surface antigen (HBsAg) to a subject suffering from chronic hepatitis B to differentiate between responder subjects and non-responder subjects that the administration of HBsAg results in an increased response to HBV antibody levels, and treating chronic hepatitis B in responder subjects using HBV therapy. Also provided are methods of excluding unresponded subjects outside a clinical study.

The invention provides a bivalent bovine viral diarrhea virus antigen protein composition, a subunit vaccine as well as a preparation method and application of the bivalent bovine viral diarrhea virus antigen protein composition and the subunit vaccine, and belongs to the technical field of genetic engineering vaccines. The bivalent bovine viral diarrhea virus antigen protein composition is prepared from a recombinant protein kozak-MLTsp-BVDV1-E2-His and a recombinant protein kozak-IgKsp-BVDV2-E2-His, the amino acid sequence of the recombinant protein kozak-MLTsp-BVDV1-E2-His is as shown in SEQ ID NO.16, and the amino acid sequence of the recombinant protein kozak-IgKsp-BVDV2-E2-His is as shown in SEQ ID NO.18. The invention further discloses a preparation method of the bivalent bovine viral diarrhea virus antigen protein composition. According to the invention, efficient expression of BVDV-1 and BVDV-2 E2 proteins is realized, high-purity E2 proteins are obtained, the safety and effectiveness of vaccines are ensured, and the antibody level of the vaccines is improved.

The invention discloses application of CpG ODN in preparation of a medicine for regulating animal immune cell activity, and relates to the technical field of animal vaccines. In the invention, the regulation of the animal immune cell activity is to promote the immune response reaction of immune cells; the step of promoting the immune response reaction of the immune cells comprises the step of promoting the immune cells to generate interferon. The CpG ODN provided by the invention can well and specifically stimulate immune cells of animals, especially pigs to release cytokines and promote the animals to generate rapid and strong immune response to immunogens; when being applied to an animal vaccine, the vaccine can stimulate animals to generate a higher antibody level in a shorter time, and can maintain the high-level antibody for a long time, and the immunogenicity of the vaccine is remarkably improved.

The invention belongs to the technical field of kit preparation, and particularly relates to preparation and application of a pertussis acute infection detection test strip based on double-T-line immunochromatography. The amino acid sequence of the recombinant protein provided by the invention is as shown in SEQ ID NO. 1. The recombinant protein is used as an antigen to prepare a double-T-line test strip for detecting the pertussis IgG antibody, and the test strip is extremely simple and convenient to operate, rapid in detection and visual and reliable in result interpretation, has excellent sensitivity, specificity and stability, can realize semi-quantitative detection of the pertussis IgG antibody, and can be used for detecting the pertussis IgG antibody. The pertussis IgG antibody detection method solves the problems that an existing pertussis IgG antibody detection method is complex in operation, long in consumed time and high in cost, whether the antibody level is in an immune protection state or an acute infection state can be preliminarily judged according to the color development condition of a detection line, and powerful support is provided for clinical pertussis infection diagnosis and disease prevention and control.

B-cell maturation antigen (BCMA) is expressed on plasma cells. The present invention provides methods for desensitizing patients in need of a solid organ transplant to anti-HLA antibodies using bispecific antibodies that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing plasma cells. In certain embodiments, the bispecific antibodies of the present invention reduce alloantibody levels and / or reduce calculated panel reactive antibody levels to facilitate solid organ transplantation and / or improve long term graft survival and / or function.

The application discloses application of citrullinated galectin-1 polypeptide in preparation of a rheumatoid arthritis diagnosis product, and belongs to the technical field of rheumatoid arthritis diagnosis. The amino acid sequence of the citrullinated galectin-1 polypeptide is GD-Cit-WSSQQGSKAVYPE; the product is used for detecting the content of anti-citrullinated galectin-1 polypeptide antibody in a biological sample of a patient, and the antibody level is significantly different between RA patients, normal healthy people and other common rheumatic immune disease patients who are easily confused with rheumatoid arthritis. The product has good sensitivity to common RA, RA with normal ESR and CRP, and anti-CCP antibody / RF negative RA patients, and has good supplementary diagnosis value for the diagnosis of RA.

The invention discloses an anti-tilapia mossambica IgM monoclonal antibody, a hybridoma cell strain and application thereof. The CDR sequence of a heavy chain variable region of the monoclonal antibody is as shown in SEQ ID NO.1-3, and the CDR sequence of a light chain variable region of the monoclonal antibody is as shown in SEQ ID NO.4-6; the monoclonal antibody can be secreted by a hybridoma cell strain with the preservation number of CCTCC (China Center For Type Culture Collection) NO: C2023153. The monoclonal antibody provided by the invention can be used for Western blot and ELISA specific detection of tilapia mossambica secretion form IgM, can be used for flow cytometry identification of tilapia mossambica IgM + B cells, has the characteristics of good specificity, high sensitivity, strong affinity and the like, can be used for structural analysis, immune response level detection and the like of tilapia mossambica IgM, and can be used for preparing a tilapia mossambica IgM immunoassay kit. And a foundation is laid for deep research of a tilapia immune system and establishment of a tilapia vaccine immune effect evaluation method taking the antibody level as an index.

The invention belongs to the technical field of genetic engineering, and particularly relates to a chimeric virus-like particle vaccine of feline coronavirus and feline panleucopenia virus and application of the chimeric virus-like particle vaccine. The invention provides chimeric virus-like particles of feline coronavirus and feline panleucopenia virus. The chimeric virus-like particles contain feline coronavirus type I S protein and feline panleucopenia virus VP2 protein. The invention also provides a preparation method and application of the chimeric virus-like particle. After the vaccine prepared from the chimeric virus-like particles is used for immunizing mice and cats, a high-titer antibody level can be generated, and the organism is stimulated to generate cellular immunity; the immunized cat can effectively resist invasion of cat coronavirus and cat panleucopenia virus. The chimeric virus-like particle has good immunogenicity and can be used for preventing and controlling cat infectious diseases.

The present application relates to the technical field of protein detection, and particularly relates to a detection method and kit for detecting anti-Nephrin antibody. The detection method comprises the following steps: using biotinylated Nephrin protein to capture anti-Nephrin antibody in a sample to be detected on a SA matrix to obtain a first complex; performing acidolysis desorption, neutralization and Protein G directed antibody immobilization on the first complex to obtain a second complex; using a biotin-streptavidin-HRP system to detect the second complex; the acidolysis desorption comprises the following steps: using an acid solution with a pH of 2-3 to treat the first complex, and treating at 35-40 DEG C and 500-800 rpm for 10-20 minutes. The method provided by the present application can accurately and quickly detect the anti-Nephrin antibody level in a sample, and has important application value.

The application discloses the field of biotechnology, and discloses a kind of nanobody targeting B cell CD20 and application thereof.The amino acid sequence of nanobody complementarity determining region CDR1~CDR3 is selected from SEQ ID NO.1~9.The nanobody provided by the application can specifically bind to B cell in human blood, thereby eliminating B cell producing pathological antibody.The nanobody provided by the application has smaller molecular weight compared with traditional antibody, is stable, low in cost, easy to express and high in expression amount, and is suitable for large-scale production.Nanobody is combined with solid phase carrier in the application, B cell in blood can be targetedly eliminated, the number of B cell in blood of patient is reduced in a short time, antibody level is reduced, thereby improving life quality, reducing complication, and providing new treatment selection for those patients who are ineffective or intolerant to traditional treatment.

The invention belongs to the technical field of biology, and particularly relates to construction of a pE248R protein 103 and 240 site conditional point mutation deletion strain and application of the strain as a vaccine. The method comprises the following steps: firstly, simultaneously mutating the 103 and 240 amino acid lysine of an African swine fever virus pE248R protein into arginine to construct a recombinant African swine fever virus strain; the average level of a p30 antibody in an animal immunized by the recombinant African swine fever virus strain exceeds 40% from the tenth day and the eleventh day respectively, animal death does not occur after attack of toxic substances, the recombinant African swine fever virus strain has good safety, and after attack of a parent ASFV, continuous increase of the p30 antibody level shows that the recombinant African swine fever virus strain can resist attack of a virulent parent ASFV, and clinical disease symptoms do not occur.

The application discloses application of chrysin in preparation of a medicine for treating primary Sjogren's syndrome and belongs to the technical field of biological medicine. The application proves that chrysin can be specifically combined with TNFR2 protein and is a new type of TNFR2 inhibitor through molecular docking, molecular dynamics simulation, CETSA experiment and SPR experiment. Animal experiments show that chrysin can significantly increase the secretion amount of saliva and tear of a mouse model of primary Sjogren's syndrome, reduce the serum SSA and SSB antibody levels, reduce lymphocyte infiltration and acinus atrophy of submandibular glands and lacrimal glands, inhibit the expression of a cytokine INF-gamma, and the drug efficacy is equivalent to that of a positive medicine hydroxychloroquine; chrysin and gaoshunyujin have a synergistic effect, and the improvement effect on primary Sjogren's syndrome is better than that of hydroxychloroquine. The application provides a new medical use of chrysin, and provides a safe and effective prevention and treatment medicine for primary Sjogren's syndrome.

The invention relates to the technical field of immunologic adjuvants, in particular to a preparation method of an inactivated vaccine containing the compound immunopotentiator, which comprises the following steps: mixing the compound immunopotentiator with an inactivated antigen and Tween 80 to prepare a water phase solution; mixing white oil, span 85 and aluminum stearate to obtain an oil phase solution; and shearing and emulsifying the oil-phase solution and the water-phase solution to obtain the inactivated vaccine. According to the preparation and application of the avian influenza triple inactivated vaccine containing the compound immunopotentiator, the specific compound immunopotentiator is prepared from all components of polyinosinic-polycytidylic acid, 2 ', 3'-cyclic guanosine monophosphate, 2 ', 3'-cyclic guanosine monophosphate and QS, the dissolution rate of insoluble drugs is increased, and the bioavailability of the drugs is improved; therefore, the retention time of the antigen in the body is prolonged to achieve the purpose of slow release, the continuous activation effect on the immune system is maintained, the cellular immune and humoral immune functions are further improved, and the antibody level and immune effect of the immunized body are further enhanced.

The application discloses a kind of green feed additive and preparation method thereof, the green feed additive, including the following mass parts of component: sugar terpenoid 30-50 parts, peach leaf extract 8-12 parts and birch truffle extract 0.1-0.5 parts.The application is compounded with sugar terpenoid, peach leaf extract and birch truffle extract, wherein, sugar terpenoid is the natural active substance extracted from camellia plant oil seed cake, peach leaf extract and birch truffle extract are both traditional Chinese medicine extract, the three are compounded, which will not cause bacterial drug resistance, and can reduce the hidden trouble of food safety;Make the weight of broiler chicken increase fast, have obvious weight gain effect to broiler chicken, and feed to weight ratio is reduced by 30.19%, significantly improve the growth performance of broiler chicken;Can enhance immunity, promote antibody secretion, accelerate immune cell proliferation, enhance antigen antibody level, to realize the rapid protection to broiler chicken.

The application discloses a recombinant protein and vaccine of a novel Middle East respiratory syndrome coronavirus, wherein the amino acid sequence of the recombinant protein comprises a sequence of two, three or four 367-602 amino acid fragments of a S protein RBD region of the Middle East respiratory syndrome coronavirus connected in series, or a sequence with more than 95% identity with the sequence of the amino acid fragments and having the same or similar biological activity. The recombinant Middle East respiratory syndrome (MERS) coronavirus vaccine prepared by mixing the target antigen with an adjuvant can produce a high-titer antibody level after immunizing an organism, and can be used for treating and / or preventing Middle East respiratory syndrome (MERS) coronavirus infection and / or disease.

The invention belongs to the technical field of biology, and particularly relates to construction and application of a recombinant African swine fever virus strain. The method comprises the following steps: firstly, simultaneously mutating 103-site and 240-site amino acid lysine of an African swine fever virus pE248R protein into arginine, and carrying out SIM (Subscriber Identity Module) mutation on the pE248R protein to construct a recombinant African swine fever virus strain; the average level of a p30 antibody in an animal immunized by the recombinant African swine fever virus strain exceeds 40% from the tenth day and the eleventh day, animal death does not occur after challenge, the recombinant African swine fever virus strain has good safety, and after ASFV immunization, the level of the p30 antibody continuously rises and the immune protection rate is 100%, which indicates that the recombinant African swine fever virus strain can resist attack of virulent parent ASFV, and has good application prospects. And clinical disease symptoms do not appear.

The invention discloses a construction method and application of a toxoplasma gondii attenuated strain RH ncl1, and belongs to the technical field of biological medicines. According to the invention, the TgNCL1 gene is knocked out to obtain the toxoplasma gondii attenuated strain with deletion of the TgNCL1 gene, the in-vitro proliferation speed of the toxoplasma gondii with deletion of the TgNCL1 gene is obviously reduced, and the pathogenicity is obviously reduced; the mouse infected with the TgNCL1 gene deletion strain is neither diseased nor dead, and has high safety to a host. After a mouse is immunized by the toxoplasma gondii attenuated strain with deletion of the TgNCL1 gene, a relatively high humoral immunity and cellular immunity antibody level is generated, a remarkable immune protection effect can be provided for reinfection of high-dose RH, PYS tachyzoites and Pru cysts, and reinfection of toxoplasma gondii can be prevented.

The present invention relates to a feed additive intended to be incorporated into the drinking water of poultry. This additive is formulated from a specific mixture of essential oils selected for their beneficial properties on poultry health; namely: - Thyme, marjoram, calyptus globulus and peppermint essential oils. Administering this additive leads to a significant increase in poultry growth, improves their immune system by increasing antibody levels, and reduces the use of antibiotics. The invention addresses a crucial need in the poultry industry by offering a natural and effective alternative to antibiotics, while simultaneously improving the zootechnical performance of poultry. It is part of a more sustainable poultry production approach and aligns with consumer expectations for safer, higher-quality products. The invention is distinguished by the precise dosage of its components, guaranteeing optimal synergy between the essential oils. It is easily integrated into existing farming practices thanks to its simple administration via the poultry's drinking water. Clinical trials have demonstrated the effectiveness of this additive, with significant results in terms of weight gain, reduced mortality rate, and improved feed conversion ratio.

The invention provides a monoclonal antibody of a humanized anti-ATR001 oligopeptide antigen, an antibody quantitative detection kit and application. The monoclonal antibody comprises a heavy chain and a light chain of a specific amino acid sequence, and the kit comprises a coated plate coated with an ATR001 oligopeptide antigen, a standard substance, a matched diluent, a horse radish peroxidase labeled goat anti-human IgG antibody, a developing solution, a stop solution and a concentrated washing solution. The ATR001 oligopeptide antigen is moderately modified, so that the ATR001 oligopeptide antigen has higher coating stability and easiness in coupling, and the sensitivity and the specificity of a detection method can be remarkably improved. The kit disclosed by the invention can be used for detecting the level of the anti-ATR001 oligopeptide antibody generated in human serum after subcutaneous injection of the ATRQbeta-001 therapeutic antihypertensive vaccine, so that an immune response and immunogenicity evaluation method is provided for clinical application of the vaccine.

The present disclosure relates to a method of diagnosing Lyme disease in a subject comprising measuring the level of B. burgdorferi peptidoglycan or the level of an antibody that specifically binds to B. burgdorferi peptidoglycan (“anti-peptidoglycan agent”). The present disclosure also relates to a method of treating a Lyme disease in a subject in need thereof comprising administering to the subject an antagonist against B. burgdorferi peptidoglycan (e.g., an anti-peptidoglycan antibody or a peptidoglycan-specific hydrolase). Antagonists (e.g., anti-peptidoglycan antibodies) suitable for the present methods are also disclosed.

This invention discloses a high-affinity mouse anti-eel IgM monoclonal antibody, a hybridoma cell line, and its applications. The mouse anti-eel IgM monoclonal antibody comprises a heavy chain variable region and a light chain variable region. The CDR region of the heavy chain variable region contains three sequences as shown in SEQ ID NO. 1-3, and the CDR region of the light chain variable region contains three sequences as shown in SEQ ID NO. 4-6. The mouse anti-eel IgM monoclonal antibody can be secreted by the hybridoma cell line ArIgMH-33G9D2G7C12, with accession number CCTCC NO: C202545. The mouse anti-eel IgM monoclonal antibody provided by this invention can be used for flow cytometry to identify eel IgM. + This monoclonal antibody, developed for B cells, can be used for the specific detection of secretory IgM in eels via ELISA and Western blot. It exhibits high specificity, sensitivity, and affinity, making it suitable for structural analysis of eel IgM and detection of immune response levels. This lays the foundation for in-depth research on the eel immune system and the establishment of methods for evaluating vaccine efficacy using antibody levels as an indicator.